Background
==========

Treatment options for SCLC after failing platinum-based (PLT) chemotherapy (CT) are limited. Combined blockade of programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) immune checkpoint pathways has anti-tumor activity with a manageable safety profile. Nivolumab is a fully human IgG4 PD-1 immune checkpoint inhibitor approved for melanoma and squamous NSCLC in the US and for melanoma in the EU and Japan. Interim efficacy and safety of nivolumab +/- ipilimumab, a CTLA-4 checkpoint inhibitor, in pretreated SCLC patients are reported.

Methods
=======

Patients with progressive disease (PD) after PLT first-line treatment were eligible, regardless of platinum sensitivity, tumor PD-L1 expression, or number of prior CT regimens. Patients were randomized to nivolumab 3 mg/kg IV Q2W or nivolumab+ipilimumab (1+1 mg/kg or 1+3 mg/kg) IV Q3W for 4 cycles, followed by nivolumab 3 mg/kg Q2W. Primary objective was objective response rate (ORR). Additional objectives included safety, progression-free survival (PFS), overall survival (OS), and biomarker analysis.

Results
=======

Of 90 patients enrolled (nivolumab, n=40; nivolumab+ipilimumab, n=50 \[nivolumab 1+ipilimumab 1, n=3; nivolumab 1+ipilimumab 3, n=47\]), 53% had ≥2 prior regimens. Efficacy results for evaluable patients are shown (Table [1](#T1){ref-type="table"}). 20% of patients in the nivolumab arm and 42% in the nivolumab+ipilimumab arms remain on treatment. Discontinuations due to treatment-related adverse events (TRAEs) occurred in 8% of nivolumab and 11% of nivolumab+ipilimumab patients. TRAEs (all grades) in ≥10% of patients included fatigue (18%), diarrhea (13%), nausea (10%), and decreased appetite (10%) with nivolumab; and diarrhea (23%), fatigue (21%), rash (21%), pruritus (19%), hypothyroidism (15%), hyperthyroidism (13%), nausea (13%), maculopapular rash (13%), and increased lipase (11%) with nivolumab 1+ipilimumab 3. Grade 3--4 TRAEs in ≥5% of patients occurred only in the nivolumab 1+ipilimumab 3 arm and included diarrhea (9%) and increased lipase (6%). Pneumonitis occurred in 2 patients in the nivolumab arm (grade 1--2) and 1 patient in the nivolumab 1+ipilimumab 3 arm (grade 3--4). One patient in the nivolumab 1+ipilimumab 3 arm had treatment-related myasthenia gravis with fatal outcome. Updated efficacy, safety, biomarker analysis, and case studies (responses in a patient with PLT-refractory disease and in a patient after crossover to nivolumab/ipilimumab) will be presented.

                                                     Nivolumab (n-40)   Nivolumab + Ipilimumab (n=46)^a^
  -------------------------------------------------- ------------------ ----------------------------------
  ORR, %                                             18                 17
                                                                        
   Complete response, %                              0                  2.2
                                                                        
   Partial response, %                               18                 15
                                                                        
   Stable disease,^b^ %                              20                 37
                                                                        
   Disease control rate, %                           38                 54
                                                                        
   Progressive disease, %                            53^c^              37
                                                                        
  Death prior to first response assessment, %        10                 6.5^d^
                                                                        
  Not evaluable (no tumor assessment follow-up), %   0                  2.2^e^
                                                                        
  Median time to objective response (months)         1.6                2.2
                                                                        
  Median DOR, months (95% CI) Range                  NR 4.1-11+         6.9 (1.5 NR) 1,5-11,1+

DOR=duration of response; NR=not reached.

^a^4 of 50 patients did not reach first tumor assessment at database lock.

^b^Of 17 patients with stage disease in the nivolumab + ipilimumab arm, 7 had confirmed partial response after databse lock, resulting in updated ORR of 32.6%.

^c^1 patient had progressive disease in the spine, requiring surgery.

^d^1 patient died due to an unrelated adverse event, 1 patient died due to treatment-related myasthenia gravis, 1 patient died due to progressive disease.

^e^1 patient had an unrelated adverse event leading to permanent discontinuation, and had no post-baseline tumor assessment.

Conclusions
===========

In this PD-L1 unselected SCLC population with progression after PLT-CT, nivolumab monotherapy and nivolumab+ipilimumab were generally well tolerated with manageable toxicity. Rare severe toxicities will require close follow-up. Durable responses occurred with nivolumab monotherapy and in combination with ipilimumab.

Trial Registry
==============

Clinical Trial Number: NCT01928394.
